3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130303:nPnCN69889 SHENYANG, China, March 3, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited fourth quarter and full year 2012 results on Tuesday, March 19, 2013 at 8:00am China Standard Time. Following the earnings announcement, 3SBio's senior management will host a conference call on Tuesday, March 19, 20138:00pm China Standard Time (8:00am US Eastern or 5:00am US Pacific) to discuss its unaudited fourth quarter and full year 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below: Conference ID: 15890708 Local dial-in: China landline: 800-819-0121 China mobile: 400-620-8038 Hong Kong : 852-2475-0994 United States: 718-354-1231 International toll-free dial-in: Hong Kong: 800930346 United States: 1-866-519-4004 United Kingdom: 080-8234-6646 International toll dial-in: 65 6723 9381 Replay- Conference ID: 15890708 A telephone replay will be available two hours after the call until March 27, 2013 at: International: 61-2-8235-5000 United States: 1-866-214-5335 Webcast A live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://www.media-server.com/m/p/bcshv7v5. A replay of the webcast will be available within one hour after the conclusion of the call. About 3SBio Inc. 3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information. Investor Contacts Bo Tan Tom Folinsbee Chief Financial Officer Director of Investor Relations 3SBio Inc. 3SBio Inc. Tel: + 86 24 2581-1820 Tel: + 852 8191-6991 ir@3SBio.com ir@3SBio.com SOURCE 3SBio Inc.
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Twitter backtracks on block feature after users revolt |
- Iran angry over U.S. sanctions, nuclear talks interrupted